In vitro dendritic cell‐induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL‐15 and dendritic cell–B‐CLL electrofusion hybrids

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical and Experimental Immunology

• Publication date

  2003-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1365-2249.2003.02047.xPMID 12519390PMCID PMC1808593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumour cell–dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen‐glycol versus electro‐fusion protocols

  2002cited by this paper
• Dendritic cells and immunotherapy for malignant disease

  2001cited by this paper
• Suppression of IL-2-Induced T Cell Proliferation and Phosphorylation of STAT3 and STAT5 by Tumor-Derived TGFβ Is Reversed by IL-151

  2001cited by this paper
• Functional monocyte‐derived dendritic cells can be generated in chronic lymphocytic leukaemia

  2001cited by this paper
• Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B‐cell chronic lymphocytic leukaemia: evidence of immune dysregulation

  2001cited by this paper
• Generation in vitro of B‐cell chronic lymphocytic leukaemia‐proliferative and specific HLA class‐II‐restricted cytotoxic T‐cell responses using autologous dendritic cells pulsed with tumour cell lysate

  2001cited by this paper
• In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells.

  2000cited by this paper
• Interleukin-15 redirects the outcome of a tolerizing T-cell stimulus from apoptosis to anergy.

  2000cited by this paper
• Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity1

  2000cited by this paper
• Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines.

  2000cited by this paper
• Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids

  2000cited by this paper
• Effects of TGF-beta on the immune system: implications for cancer immunotherapy.

  1999cited by this paper
• Dendritic cells: development, function and potential use for cancer immunotherapy.

  1999cited by this paper
• Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells.

  1999cited by this paper
• Effects of TGF-β on the immune system: implications for cancer immunotherapy

  1999cited by this paper
• Impediments to successful immunotherapy.

  1999cited by this paper
• Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti tumour cytotoxic T cells.

  1998cited by this paper
• Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.

  1998cited by this paper
• Quiescence-inducing and antiapoptotic activities of IL-15 enhance secondary CD4+ T cell responsiveness to antigen.

  1998cited by this paper
• In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells.

  1998cited by this paper
• Type I IFNs enhance the terminal differentiation of dendritic cells.

  1998cited by this paper
• Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the philadelphia translocation and can induce a CML‐specific primary cytotoxic T‐cell response

  1997cited by this paper
• Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.

  1997cited by this paper
• Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells

  1997cited by this paper
• Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway.

  1997cited by this paper
• Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

  1996cited by this paper
• CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

  1996cited by this paper
• Electrofusion between heterogeneous-sized mammalian cells in a pellet: potential applications in drug delivery and hybridoma formation.

  1996cited by this paper
• Peptide‐pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA‐A*0201‐binding peptides from the Melan‐A/MART‐1 self antigen

  1996cited by this paper
• Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily.

  1995cited by this paper
• Mechanically facilitated cell-cell electrofusion.

  1994cited by this paper
• Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells.

  1994cited by this paper
• B‐cell chronic lymphocytic leukaemia cells express and release transforming growth factor‐β

  1992cited by this paper
• Introduction of soluble protein into the class I pathway of antigen processing and presentation.

  1988cited by this paper
• Cells process exogenous proteins for recognition by cytotoxic T lymphocytes.

  1988cited by this paper

• Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges

  2026cites this paper
• A Novel Heat Shock Protein 70-Based Vaccine Prepared from DC Tumor Fusion Cells: An Update.

  2023cites this paper
• A Novel Heat Shock Protein 70-based Vaccine Prepared from DC-Tumor Fusion Cells.

  2018cites this paper
• Therapeutic protein deimmunization by T‐cell epitope removal: antigen‐specific immune responses in vitro and in vivo

  2017influential citation
• Etude de la perméabilisation de la membrane plasmique et des membranes des organites cellulaires par des agents chimiques et physiques

  2013cites this paper
• impairs self-renewal and partially restores myelopoiesis in leukemic CD34+ stem/progenitor cells α Re-introduction of C/EBP

  2013cites this paper
• Dendritic/tumor fusion cells as cancer vaccines.

  2012cites this paper
• High‐resolution analyses of cell fusion dynamics in a biochip

  2012cites this paper
• Preparation of a heat-shock protein 70-based vaccine from DC-tumor fusion cells.

  2011cites this paper
• Cell Fusion and Dendritic Cell-Based Vaccines

  2011cites this paper
• The use of antigen presenting cell/tumour cell hybrids for the in vitro induction of tumour-specific T cells

  2011influential citation
• Progress in Tumor-Dentritic Cell Hybrid Vaccines*: Progress in Tumor-Dentritic Cell Hybrid Vaccines*

  2010cites this paper
• Immunological and molecular studies for the development of vaccine therapy for chronic lymphocytic leukemia

  2010cites this paper
• Wilms' tumor 1 as a novel target for immunotherapy of leukemia.

  2010cites this paper
• Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties

  2009cites this paper
• Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia Cells

  2008cites this paper
• Cell fusion: from hybridoma to dendritic cell-based vaccine

  2008cites this paper
• Type 1‐polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia

  2008cites this paper
• Blood dendritic cells in patients with chronic lymphocytic leukaemia.

  2008cites this paper
• In vivo anti-tumor effect of hybrid vaccine of dendritic cells and esophageal carcinoma cells on esophageal carcinoma cell line 109 in mice with severe combined immune deficiency.

  2008cites this paper
• Identification of Tumour Associated Antigens as Potential Targets for the Immunotherapy of B-cell Chronic Lymphocytic Leukaemia (B-CLL)

  2008cites this paper
• Dendritic cell vaccines for leukemia patients

  2007cites this paper
• Cellular immune therapy for chronic lymphocytic leukemia.

  2007cites this paper
• University of Groningen Reintroduction of C/EBP alpha in leukemic CD34(+) stem/progenitor cells impairs self- renewal and partially restores myelopoiesis Schepers,

  2007cites this paper
• Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma

  2007cites this paper
• Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy.

  2007cites this paper
• Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies

  2006cites this paper
• Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia

  2006cites this paper
• Vaccine- and immune-based therapy in chronic lymphocytic leukemia.

  2006cites this paper
• Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate

  2006cites this paper
• Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.

  2006cites this paper
• Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells

  2005influential citation
• Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia

  2005cites this paper
• Dendritic cells differentiated in the presence of IFN‐β and IL‐3 are potent inducers of an antigen‐specific CD8+ T cell response

  2005cites this paper
• IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells.

  2005cites this paper
• Vaccine strategies to treat lymphoproliferative disorders.

  2005cites this paper
• Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer.

  2005cites this paper
• Exposure to the electrofusion process can increase the immunogenicity of human cells

  2005cites this paper
• mRNA expression of tumor associated antigens in patients with chronic lymphocytic leukemia

  2005cites this paper
• Dendritic cell fusion vaccines for cancer immunotherapy

  2005cites this paper
• Loading DCs with Ag.

  2004cites this paper
• Dendritic Cell-Tumor Fusion Vaccines for Renal Cell Carcinoma

  2004cites this paper
• Phenotypic and functional characterization of monocyte‐derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19+ cells in vivo and in vitro

  2004cites this paper
• Generation of dendritic cell–tumor cell hybrids by electrofusion for clinical vaccine application

  2004cites this paper
• Cancer immunotherapy: simply cell biology?

  2003cites this paper
• A study of the proteins responsible for stimulating B-CLL-specific T-cell responses by autologous dendritic cells pulsed with tumour cell lysate.

  2003cites this paper
• Dendritic Cells and their Potential Therapeutic Role in Haematological Malignancy

  2003cites this paper
• Expression of RHAMM / CD 168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia

  year unknowncites this paper